Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Phase II Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome

NCT02569125 is registered in ClinicalTrials.gov with Jochen Roessler as lead sponsor.

NCT NCT02569125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02569125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Phase II Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome
Lead sponsor
Jochen Roessler
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2016
Completion date
February 29, 2016
Enrollment
0 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

segmental overgrowth syndrome